Erik Schulwolf


I specialize in advising cutting-edge life sciences companies on reimbursement and compliance issues related to their products.

Erik Schulwolf’s practice involves extensive work with molecular diagnostic laboratories and manufacturers of diagnostic tests on issues including reimbursement from government and private payers, compliance with fraud and abuse and federal price reporting laws, and advocacy with federal and state agencies. Erik also provides reimbursement, compliance, and federal and state government strategies advice to pharmaceutical manufacturers and providers.

As an associate in the Life Sciences Coverage & Payment group, Erik has worked with medical device manufacturers and healthcare providers on a wide array of reimbursement and compliance matters under federal and state law. Erik has considerable experience with developing reimbursement strategies, preparing advocacy approaches with federal agencies (in particular, the Centers for Medicare & Medicaid Services), and drafting federal and state legislation.


  • Harvard Law School, J.D., cum laude, 2015
  • Amherst College, B.A., magna cum laude, 2010

Bar and Court Admissions

  • Massachusetts


  • "The History of Rebates in the Drug Supply Chain and HHS’ Proposed Rule to Change Safe Harbor Protection for Manufacturer Rebates," Foley Hoag White Paper (March 2019)

Honors & Involvement

  • Senior Policy Editor, Harvard Law & Policy Review

Speaking Engagements

  • "Demystifying the CMS CLFS Pricing Process," 22nd Semi-Annual Diagnostic Coverage & Reimbursement Conference (December 2022)
  • “Outlook on Value-Based Contracting – Market Realities and Considerations,” CBI’s Strategic Medicare Contracting Forum (November 2019)